Thanks Obama: POTUS’ nomination of Robert Califf may leave Big Pharma in complete control over the FDA… he took money from 23 drug companies
by: Daniel Barker
NaturalNews.com
Sunday, March 06, 2016
It’s now official: President Obama’s nomination of Robert Califf as the new head of the Food and Drug Administration (FDA) has just been approved by the U.S. Senate.
This is a particularly worrisome development, due to Califf’s strong ties to the pharmaceutical industry, and although many in Washington (such as Bernie Sanders) and elsewhere have voiced strong opposition to the nomination, in the final vote only four senators opposed his appointment.
Califf, who until recently held the post of chancellor of clinical and translational research at Duke University, has worked closely with Big Pharma and has received money from 23 different drug companies, including such industry heavyweights as Merck, Johnson & Johnson, Lilly and GSK.
As reported by Signs of the Times:
“Not merely receiving research funds, Califf also served as a high level Pharma officer, say press reports. Medscape, the medical website, discloses that Califf ‘served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech.’ Portola Pharmaceuticals says Califf served on its board of directors until leaving for the FDA.
“In disclosure information for a 2013 article in Circulation, Califf also lists financial links to Gambro, Regeneron, Gilead, AstraZeneca, Roche and other companies and equity positions in four medical companies. Gilead is the maker of the $1000-a-pill hepatitis C drug AlterNet recently wrote about. This is FDA commissioner material?”
Califf says working with Big Pharma is ‘a very good thing’
The Rest…HERE
